vs
Side-by-side financial comparison of Dayforce (DAY) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $481.6M, roughly 1.3× Dayforce). Royalty Pharma plc runs the higher net margin — 34.4% vs -40.9%, a 75.3% gap on every dollar of revenue. On growth, Dayforce posted the faster year-over-year revenue change (9.5% vs 4.8%). Over the past eight quarters, Dayforce's revenue compounded faster (9.8% CAGR vs 4.6%).
Dayforce, Inc., formerly Ceridian, is an American human resources software and services company.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
DAY vs RPRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $481.6M | $622.0M |
| Net Profit | $-196.8M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 6.3% | 62.4% |
| Net Margin | -40.9% | 34.4% |
| Revenue YoY | 9.5% | 4.8% |
| Net Profit YoY | -9940.0% | 2.9% |
| EPS (diluted) | $-1.23 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $622.0M | ||
| Q3 25 | $481.6M | $609.3M | ||
| Q2 25 | $464.7M | $578.7M | ||
| Q1 25 | $481.8M | $568.2M | ||
| Q4 24 | $465.2M | $593.6M | ||
| Q3 24 | $440.0M | $564.7M | ||
| Q2 24 | $423.3M | $537.3M | ||
| Q1 24 | $431.5M | $568.0M |
| Q4 25 | — | $214.2M | ||
| Q3 25 | $-196.8M | $288.2M | ||
| Q2 25 | $21.3M | $30.2M | ||
| Q1 25 | $14.9M | $238.3M | ||
| Q4 24 | $10.8M | $208.2M | ||
| Q3 24 | $2.0M | $544.0M | ||
| Q2 24 | $-1.8M | $102.0M | ||
| Q1 24 | $7.1M | $4.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 47.0% | — | ||
| Q3 24 | 45.8% | — | ||
| Q2 24 | 44.1% | — | ||
| Q1 24 | 47.6% | — |
| Q4 25 | — | 62.4% | ||
| Q3 25 | 6.3% | 70.1% | ||
| Q2 25 | 9.1% | 36.3% | ||
| Q1 25 | 6.4% | 94.0% | ||
| Q4 24 | 6.1% | 60.9% | ||
| Q3 24 | 4.7% | — | ||
| Q2 24 | 3.3% | 50.2% | ||
| Q1 24 | 9.4% | -13.0% |
| Q4 25 | — | 34.4% | ||
| Q3 25 | -40.9% | 47.3% | ||
| Q2 25 | 4.6% | 5.2% | ||
| Q1 25 | 3.1% | 41.9% | ||
| Q4 24 | 2.3% | 35.1% | ||
| Q3 24 | 0.5% | 96.3% | ||
| Q2 24 | -0.4% | 19.0% | ||
| Q1 24 | 1.6% | 0.8% |
| Q4 25 | — | $0.49 | ||
| Q3 25 | $-1.23 | $0.67 | ||
| Q2 25 | $0.13 | $0.07 | ||
| Q1 25 | $0.09 | $0.55 | ||
| Q4 24 | $0.07 | $0.46 | ||
| Q3 24 | $0.01 | $1.21 | ||
| Q2 24 | $-0.01 | $0.23 | ||
| Q1 24 | $0.04 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $627.6M | $618.7M |
| Total DebtLower is stronger | $631.1M | $9.0B |
| Stockholders' EquityBook value | $2.7B | $9.7B |
| Total Assets | $8.7B | $19.6B |
| Debt / EquityLower = less leverage | 0.23× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $618.7M | ||
| Q3 25 | $627.6M | $938.9M | ||
| Q2 25 | $625.2M | $631.9M | ||
| Q1 25 | $557.3M | $1.1B | ||
| Q4 24 | $579.7M | $929.0M | ||
| Q3 24 | $494.1M | $950.1M | ||
| Q2 24 | $465.4M | $1.8B | ||
| Q1 24 | $392.5M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | $631.1M | $8.9B | ||
| Q2 25 | $631.8M | $8.0B | ||
| Q1 25 | $632.4M | $7.6B | ||
| Q4 24 | $1.2B | $7.6B | ||
| Q3 24 | $1.2B | $7.6B | ||
| Q2 24 | $1.2B | $7.6B | ||
| Q1 24 | $1.2B | $6.1B |
| Q4 25 | — | $9.7B | ||
| Q3 25 | $2.7B | $9.6B | ||
| Q2 25 | $2.7B | $9.5B | ||
| Q1 25 | $2.6B | $9.8B | ||
| Q4 24 | $2.5B | $10.3B | ||
| Q3 24 | $2.6B | $10.3B | ||
| Q2 24 | $2.5B | $9.8B | ||
| Q1 24 | $2.4B | $9.9B |
| Q4 25 | — | $19.6B | ||
| Q3 25 | $8.7B | $19.3B | ||
| Q2 25 | $8.5B | $18.3B | ||
| Q1 25 | $9.5B | $17.6B | ||
| Q4 24 | $9.1B | $18.2B | ||
| Q3 24 | $8.1B | $18.0B | ||
| Q2 24 | $9.0B | $17.7B | ||
| Q1 24 | $10.8B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.23× | 0.93× | ||
| Q2 25 | 0.23× | 0.84× | ||
| Q1 25 | 0.24× | 0.78× | ||
| Q4 24 | 0.47× | 0.74× | ||
| Q3 24 | 0.47× | 0.74× | ||
| Q2 24 | 0.49× | 0.78× | ||
| Q1 24 | 0.50× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.2M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $827.1M | ||
| Q3 25 | $31.2M | $702.6M | ||
| Q2 25 | $112.7M | $364.0M | ||
| Q1 25 | $49.6M | $596.1M | ||
| Q4 24 | $81.0M | $742.5M | ||
| Q3 24 | $91.8M | $703.6M | ||
| Q2 24 | $99.2M | $658.2M | ||
| Q1 24 | $9.1M | $664.6M |
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | 5.29× | 12.06× | ||
| Q1 25 | 3.33× | 2.50× | ||
| Q4 24 | 7.50× | 3.57× | ||
| Q3 24 | 45.90× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 1.28× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAY
| Dayforce Recurring | $333.0M | 69% |
| Cloud And Bureau Professional Services And Other | $78.5M | 16% |
| Float | $42.2M | 9% |
| Powerpay Recurring | $19.7M | 4% |
| Other Recurring | $8.2M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
